76 related articles for article (PubMed ID: 31920132)
1. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma.
Moser JC; Wei G; Colonna SV; Grossmann KF; Patel S; Hyngstrom JR
Acta Oncol; 2020 Apr; 59(4):434-437. PubMed ID: 31920132
[No Abstract] [Full Text] [Related]
2. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
[TBL] [Abstract][Full Text] [Related]
3. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.
Ibrahim T; Mateus C; Baz M; Robert C
Cancer Immunol Immunother; 2018 Oct; 67(10):1571-1578. PubMed ID: 30056599
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
Bender C; Enk A; Gutzmer R; Hassel JC
Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study.
Mowery YM; Patel K; Chowdhary M; Rushing CN; Roy Choudhury K; Lowe JR; Olson AC; Wisdom AJ; Salama JK; Hanks BA; Khan MK; Salama AKS
Radiother Oncol; 2019 Sep; 138():114-120. PubMed ID: 31252292
[TBL] [Abstract][Full Text] [Related]
6. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Morrison C; Pabla S; Conroy JM; Nesline MK; Glenn ST; Dressman D; Papanicolau-Sengos A; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Lenzo FL; Omilian A; Bshara W; Zibelman M; Ghatalia P; Dragnev K; Shirai K; Madden KG; Tafe LJ; Shah N; Kasuganti D; de la Cruz-Merino L; Araujo I; Saenger Y; Bogardus M; Villalona-Calero M; Diaz Z; Day R; Eisenberg M; Anderson SM; Puzanov I; Galluzzi L; Gardner M; Ernstoff MS
J Immunother Cancer; 2018 May; 6(1):32. PubMed ID: 29743104
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
Leroy M; Desmedt E; Deramoudt L; Vasseur M; Odou P; Béhal H; Décaudin B; Mortier L; Simon N
Melanoma Res; 2024 Jun; 34(3):258-264. PubMed ID: 38489575
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.
Ochenduszko S; García Sanchez J; Fita MJJ; González-Barrallo I; Herrero Colomina J; Mujika K; Beveridge RD; Martínez SR; Lafuente BS; Tomas AC; Jaime AB; Cerezuela Fuentes P; Fra PL; Peeters AG; Meana García JA; García MAA; Altozano JP; Cancela M; Puchades AM; Roca FF; Maiques IM
Pigment Cell Melanoma Res; 2023 Sep; 36(5):388-398. PubMed ID: 37243929
[TBL] [Abstract][Full Text] [Related]
9. Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies.
Hock BD; McKenzie JL; Strother M; Goddard L; Butt L; Currie MJ
Cancer Immunol Immunother; 2020 Dec; 69(12):2453-2464. PubMed ID: 32556495
[TBL] [Abstract][Full Text] [Related]
10. Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma.
Foo T; Tapia Rico G; Brown MP
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32699060
[TBL] [Abstract][Full Text] [Related]
11. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Sullivan RJ; Atkins MB; Kirkwood JM; Agarwala SS; Clark JI; Ernstoff MS; Fecher L; Gajewski TF; Gastman B; Lawson DH; Lutzky J; McDermott DF; Margolin KA; Mehnert JM; Pavlick AC; Richards JM; Rubin KM; Sharfman W; Silverstein S; Slingluff CL; Sondak VK; Tarhini AA; Thompson JA; Urba WJ; White RL; Whitman ED; Hodi FS; Kaufman HL
J Immunother Cancer; 2018 May; 6(1):44. PubMed ID: 29848375
[TBL] [Abstract][Full Text] [Related]
12. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies.
Buder-Bakhaya K; Benesova K; Schulz C; Anwar H; Dimitrakopoulou-Strauss A; Weber TF; Enk A; Lorenz HM; Hassel JC
Cancer Immunol Immunother; 2018 Feb; 67(2):175-182. PubMed ID: 29018908
[TBL] [Abstract][Full Text] [Related]
13. Sex Differences in Odds of Brain Metastasis and Outcomes by Brain Metastasis Status after Advanced Melanoma Diagnosis.
Cioffi G; Ascha MS; Waite KA; Dmukauskas M; Wang X; Royce TJ; Calip GS; Waxweiler T; Rusthoven CG; Kavanagh BD; Barnholtz-Sloan JS
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730723
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy timing and use in patients with advanced melanoma at the end of life: A retrospective cohort study.
van Lith PEA; Schreuder K; Jalving M; Reyners AKL; Been LB; Rácz E; Fransen HP; Louwman MWJ
J Dermatol; 2024 Apr; 51(4):584-591. PubMed ID: 38078557
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC.
Cui P; Li R; Huang Z; Wu Z; Tao H; Zhang S; Hu Y
Sci Rep; 2020 Aug; 10(1):13160. PubMed ID: 32753702
[TBL] [Abstract][Full Text] [Related]
17. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
Machado MAÁ; de Moura CS; Chan K; Curtis JR; Hudson M; Abrahamowicz M; Jamal R; Pilote L; Bernatsky S
Sci Rep; 2020 Sep; 10(1):14607. PubMed ID: 32884119
[TBL] [Abstract][Full Text] [Related]
18. First-line immunotherapy versus targeted therapy in patients with
Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
[No Abstract] [Full Text] [Related]
19. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
Sullivan RJ
Lancet; 2020 May; 395(10236):1524-1525. PubMed ID: 32416774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
